Prolia fails Phase III breast cancer trial.- Amgen + Daiichi Sankyo.
Daiichi Sankyo Company, Limited announced that on 1 February, 2018 in PST Amgen Inc. made an announcement regarding the top-line results from its Global Phase III D-CARE trial in which Daiichi Sankyo also participated.
Amgen Inc.�s D-CARE, placebo-controlled trial, evaluated AMG 162 (generic name: denosumab) as adjuvant treatment for women with high-risk, early stage breast cancer receiving standard of care neoadjuvant or adjuvant cancer therapy. The trial did not meet its primary endpoint of bone metastasis-free survival. Adverse events observed in patients treated with denosumab were generally consistent with the known safety profile. Detailed results will be submitted to a future medical conference or publication.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.